Arid1a Inhibition During T Cell Preparation for Memory Persistence

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing CAR-T cell therapies for B cell malignancies face challenges with frequent relapses and inability to achieve complete remission due to the intrinsic properties of T cells, with early memory T cells being more favorable for long-term antitumor activity.

Innovation Solution

Treating naïve T cells with an inhibitor of AT-rich interaction domain 1A (Arid1a) during activation promotes memory function, enhancing their therapeutic efficacy in anti-cancer immunity by preparing T cells for adoptive T cell therapy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If T cells are activated for CAR-T cell therapy, then antitumor activity is improved, but T cell differentiation reduces long-term persistence

Engineering Contradiction:

Improveantitumor activityVSAvoidlong-term persistence

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The invention applies preliminary action by treating T cells with an Arid1a inhibitor during the activation phase (before adoptive transfer), which pre-conditions the T cells to maintain a memory phenotype. This preliminary intervention ensures that the T cells are primed for both immediate antitumor activity and long-term persistence, resolving the contradiction between activation-induced efficacy and differentiation-induced exhaustion.

Inventive Principle:

Principle #10Preliminary action

2Productivity

If T cells are expanded early after infusion, then primary objective responses are improved, but long-term persistence is compromised

Engineering Contradiction:

Improveprimary objective responsesVSAvoidlong-term persistence

Core Design Contradiction:

ProductivityVSDuration of action of moving object

Solution Approach 1:

The invention employs parameter changes by modifying the molecular environment during T cell activation through Arid1a inhibition. This changes the differentiation trajectory parameters, allowing T cells to expand and respond effectively while simultaneously maintaining memory program expression, thus achieving both high primary responses and long-term persistence without the traditional trade-off.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If T cell differentiation is promoted, then proliferative capacity increases, but memory function and long-term survival decrease

Engineering Contradiction:

Improveproliferative capacityVSAvoidmemory function

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The Arid1a inhibitor acts as an intermediary molecule that mediates between the conflicting demands of proliferation and memory maintenance. By inhibiting Arid1a, the invention creates a molecular environment that allows T cells to undergo necessary proliferation while simultaneously preserving memory program expression, effectively decoupling the normally inverse relationship between these two functions.

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentUS20250223552A1Method for preparing t cells for adoptive t cell therapy

Publication Date: 2025.07.10 ST JUDE CHILDRENS RES HOSPITAL INC

AI summary

Disclosed is a method for preparing T cells for adoptive T cell therapy by contacting a population of activated T cells with an AT-rich interaction domain 1A (Aridla) inhibitor. Also disclosed is a kit, a population of T cells or engineered T cells produced by the method and use of the same in adoptive T cell therapy and the treatment of cancer.